# Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia

> **NCT02822326** · PHASE1 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Acute Leukemia

## Interventions

- **BIOLOGICAL:** CD19-CAR-T2 Cells

## Key facts

- **NCT ID:** NCT02822326
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822326, "Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02822326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*